HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Aug. 16, 2022 (HealthDay News) -- During the omicron-predominant period, three doses of an mRNA COVID-19 vaccine were associated with improved protection against infection for patients receiving dialysis, but patients with low circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) immunoglobulin G (IgG) antibodies have increased infection risk, regardless of vaccination status, according to a study published online Aug. 15 in the Journal of the American Society of Nephrology.
Maria Montez-Rath, Ph.D., from Stanford University in California, and colleagues followed monthly semiquantitative SARS-CoV-2 RBD IgG index values in a randomly selected nationwide cohort of patients receiving dialysis. The relative risk for documented SARS-CoV-2 infection was estimated by vaccination and circulating RBD IgG during the omicron-dominant period of Dec. 25, 2021, to Jan. 31, 2022.
The researchers found that 25 percent of the 3,576 patients receiving dialysis received a third mRNA vaccine dose as of Dec. 1, 2022. Early antibody responses to the third dose were generally robust, with a median peak index IgG value of 150. SARS-CoV-2 infection was documented in 7 percent of patients during the study period. Patients without vaccination and with one or two versus three doses had a higher risk for infection. The risk for infection was higher among patients with circulating RBD IgG <23 versus IgG ≥23, irrespective of vaccine doses.
"Measuring a person's circulating antibody response to SARS-CoV-2 virus may help us identify the highest risk persons eligible for enhanced protection among patients on dialysis, and other immunocompromised or frail populations," a coauthor said in a statement.
Several authors disclosed financial ties to Ascend Clinical Laboratories.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 21, 2022